Importance of Pediatric Studies in SARS-CoV-2 Vaccine Development.
COVID-19
SARS-CoV2
pediatric
vaccine
Journal
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
ISSN: 1551-6776
Titre abrégé: J Pediatr Pharmacol Ther
Pays: United States
ID NLM: 101089851
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
03
2021
accepted:
20
03
2021
entrez:
26
5
2021
pubmed:
27
5
2021
medline:
27
5
2021
Statut:
ppublish
Résumé
Vaccination efforts against COVID-19 must include the pediatric population, not only to protect children and their families from the virus, but also to support a safe return to in-person schooling. Given the novel methodologies and targets used in the COVID-19 vaccines and the potential for multisystem inflammatory syndrome-children, it is insufficient to extrapolate safety and efficacy data between different vaccine candidates or from adult studies. Adequate enrollment in pediatric studies for COVID-19 vaccines is crucial. The Pediatric Pharmacy Association supports continued research, surveillance, and transparency for COVID-19 vaccines in the pediatric population, including those younger than 12 years of age.
Identifiants
pubmed: 34035689
doi: 10.5863/1551-6776-26.4.418
pmc: PMC8139573
doi:
Types de publication
Editorial
Langues
eng
Pagination
418-421Informations de copyright
Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2021.
Déclaration de conflit d'intérêts
Disclosure. The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria.
Références
Pediatrics. 2016 Sep;138(3):
pubmed: 27573088
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Am J Health Syst Pharm. 2020 Dec 4;77(24):2112-2113
pubmed: 32871003
J Infect Dis. 2021 Feb 13;223(3):362-369
pubmed: 33119738